New hope for lung cancer: drug duo targets tough-to-treat SCLC

NCT ID NCT05903092

Recruiting now Disease control Sponsor: Hirva Mamdani Source: ClinicalTrials.gov ↗

First seen Feb 02, 2026 · Last updated May 17, 2026 · Updated 12 times

Summary

This study tests two immunotherapy drugs (monalizumab and durvalumab) with or without chemotherapy for small cell lung cancer (SCLC). It includes 84 adults with either extensive-stage or limited-stage SCLC. The goal is to see if the combination helps control the cancer longer and is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Indiana University Melvin and Bren Simon Comprehensive Cancer Center
RECRUITING

Indianapolis, Indiana, 46202, United States

Contact Email: •••••@•••••

Contact
Karmanos Cancer Center (Wayne State University)
RECRUITING

Detroit, Michigan, 48201, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact
University of Iowa Hospitals and Clinics
RECRUITING

Iowa City, Iowa, 52242, United States

Contact Email: •••••@•••••

Contact
University of Virginia Health System
RECRUITING

Charlottesville, Virginia, 22908, United States

Contact Email: •••••@•••••

Contact

Conditions

Explore the condition pages connected to this study.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER EXTENSIVE-STAGE SMALL-CELL LUNG CANCER LIMITED STAGE SMALL-CELL LUNG CANCER SCLC SMALL CELL LUNG CANCER